Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« Cell stress inflames the gut: New insights into chronic bowel inflammation

HMPC Q&A Documents on Herbal Medicinal Products published »

Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes

June 25, 2014 by larryhbern

If you know diabetes – it opens a door to all of medicine.

Posted in Uncategorized | Leave a Comment

Leave a Reply Cancel reply

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Email Address

Join 9,459 other subscribers
Recent Posts
- Creating a Twitter Space for @pharma_BI for Live Broadcasts March 14, 2023
- The Vibrant Philly Biotech Scene: Recent Happenings & Deals March 11, 2023
- Peak oxygen uptake (VO2peak) quantified fitness: Lifelong and late-onset athletes had higher VO2peak than non-athletes March 7, 2023
- Merck’s sotatercept overachieves, PCSK9 inhibitor passes phase 2 March 6, 2023
- Bacterial multidrug resistance problem solved by a broad-spectrum synthetic antibiotic March 1, 2023
- Genetic variation causes human lupus, systemic lupus erythematosus (SLE) February 23, 2023
- Mimicking vaginal cells and microbiome interactions on chip microfluidic culture February 14, 2023
- Press Release for Five Bilingual BioMed e-Series in English and in Spanish January 29, 2023
- 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
- Verily announced other organizational changes, 1/13/2023 January 16, 2023
Archives
Archives
Categories
Categories
Meta

%d bloggers like this: